TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Accumulative percentage of LVT formation at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Bleeding events (ISTH criteria) through the study
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects who maintain undetectable HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from start of induction to fetal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Engraftment potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With ≥ 5% Reduction in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Injection Site Reactions (ISRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects with Clinically Significant Change From Baseline in Vital Signs, Laboratory Parameters and 12-lead Electrocardiogram (ECG) Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Malondialdehyde (MDA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in Superoxide dismutase (SOD) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Temporally Associated Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of FES PET/MRI for Evaluating Endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of FES PET/MRI for Evaluating Endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal radiographic fracture healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of intervention delivery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Work and Social Adjustment Scale (W&SAS)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Self-Critical Rumination Scale (SCRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of procalcitonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of thrombocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Level of leukocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pharmacokinetic parameters (Cmax, AUC, terminal elimination half life, total clearance, volume of distribution)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour IOP control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Pathologic complete remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic partial remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CVC colonization
Endpoint domain: Adverse events/effects
Primary endpoint: CRBSI
Endpoint domain: Adverse events/effects
Primary endpoint: CLABSI
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in syphilis morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Acute Treatment-related Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Late Treatment-related Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients Achieving a Prostate Specific Antigen-Complete Response (PSA-CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clearance of SK Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: serum level of high sensitive CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Time between clinical diagnosis of brain death and realization of CT angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Any Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Adverse Events Categorized by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Serum Potassium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rate and severity of complications after interval appendectomy
Endpoint domain: Adverse events/effects
Primary endpoint: incidence and rate of appendectomies during the first year of diagnosis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change in inspiratory muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Long term safety profile
Endpoint domain: Adverse events/effects
Primary endpoint: total amount of COC (cumulus-oocyte-complex)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Circulating biomarkers of cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postanesthetic emergence agitation
Endpoint domain: Adverse events/effects
Primary endpoint: Behavior improvement on the modified Houpt behavioral rating scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feasibility of Using Virtual Reality Meditation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of Using Virtual Reality Meditation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Experience of Using Virtual Reality Meditation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Management of bothersome bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed social behaviours
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: ART initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Soft-tissue vertical displacement (STVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radioactivity Biodistribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radioactivity accumulation in known tumor sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in leisure activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: dermis density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in best-corrected Snellen visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diameter of the sulcus blood vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sensitivity and specificity for assignment to case or control groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LVM change per Cardiac MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 3 year progression free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Diagnostic efficiency of flexible bronchoscopy in peripheral lung lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Metabolite concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression to dysplasia/cancer
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with a glycolysis profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with an oxidative profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects With Potential Immune-mediated Disease (pIMDs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Medically Significant Conditions (MSCs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Pregnant Subjects Reporting Pregnancy Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in Biomechanical Assessment (Gait Parameters and EMG Activation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Video recording of cystoscopic examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PTSD diagnostic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in knowledge, confidence and satisfaction regarding patient-engagement methodology
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Erythema 1 Day After UV Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Erythema 2 Days After UV Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Erythema 3 Days After UV Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Lactulose/mannitol recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum zonulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Behaviour assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of exacerbations treated with steroids and/or antibiotics for ≥3 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of exacerbations of COPD that require hospital admission and treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Parameters of the metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bioavailability of protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False Negative Rate (FNR) of Sentinel Lymph Node Biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: door to device (D2D) time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term post operative pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Prevalence of middle ear disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasopharyngeal carriage of vaccine type pneumococci
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHO Disability Assessment Schedule 2.0 (WHODAS-II)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: BMI after school entrance at 6 years of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of children with overweight/obesity at 6 years of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: clinical pregnancy rate per transfer cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: numbers of patients having OHSS
Endpoint domain: Adverse events/effects
Primary endpoint: oocyte yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oocyte maturity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circumference and length of the Achilles allograft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor parkinsonian symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: constipation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of laryngeal complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and seriousness of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Platelet Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum Concentration (Cmax) of Radiolabeled [14C]E2027
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum (Peak) Concentration (Tmax) of Radiolabeled [14C]E2027
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC(0-inf)) of Radiolabeled [14C]E2027
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correctness of response
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Combined Early and Late Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence (Hours on Therapy)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in lung function test values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peer-supportive organizational climate
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mental Health Stigma
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peer Worker Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma HIV RNA kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of the size of the proviral HIV reservoir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to viral rebound during ATI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Timed-Up and Go (TUG) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of 30 seconds sit to stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of muscle strength of the lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Skin Irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: altered bone metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Daily sitting time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: KRAS, NRAS et BRAF mutational status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to complete anal wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Treatment Failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With CTCAE Graded Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Antiretroviral therapy adherence levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Guanfacine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Guanfacine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximum Plasma Concentration (Tmax) of Guanfacine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability measured by the Sheehan Disability Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: MET Level (Exercise capacity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tremor amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximally tolerated aspirin dose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic ultrasound findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate clinical and parasitological response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum phosphorus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Clinically Significant Cancer
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in AUEC0-4 for Plasma Postprandial Glucose (PPG) Compared to Placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in sCD14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Continuous Hemoglobin evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Death or graft loss
Endpoint domain: Mortality/survival
Primary endpoint: Delay onset of sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percentage of patients achieving complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in The MATRICS Consensus Cognitive Battery (MCCB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in Neuroimage changes in Magnetic Resonance Imaging (MRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: changes in Gamma oscillation intensity (40-80 Hz) over the left and right frontal lobe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: improvement of fetid crusts and atrophy of the mucous bone covering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Birmingham IBS questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: adequate relief (IBS-AR)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Whole-gut transit time (WGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area under the curve of administration window (AUC0-12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with diagnosis of adenomyosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in lipid plaque content in coronary artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major pathological response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative chest-tube output after 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Quantification of nerve and spinal cord impairment (QOSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Expanded Disability Status Scale (EDSS)/ Functional Systems (FS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline anti-aquaporin 4 antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Periacetabular osteolysis frequency change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Periacetabular osteolysis size change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Stable Platelet Response of at Least 50,000/µL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Effectiveness of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase II Dose (RP2D) of Lenalidomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time for laparoscopic skills test (LASTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained virological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of cognitive measures scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of Ventilator-Associated Pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Change in average Unified Parkinson's Disease Rating Scale Part III motor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Mean TMax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-240
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK-estimated Nicotine Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Motivation for PrEP
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in PrEP uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention